Medivir AB

Medivir AB is dedicated to improving the lives of cancer patients through the development of transformative drugs. With a focus on areas where medical needs are unmet, Medivir AB develops innovative pharmaceuticals targeted at indications where existing therapies are limited or lacking, offering significant improvements to patients' lives.

Medivir AB is at the forefront of developing fostroxacitabine bralpamide (fostrox), a targeted chemotherapy designed to selectively treat liver cancer cells while minimizing side effects. This innovative approach highlights Medivir AB's commitment to pioneering advancements in oncology and providing effective, patient-focused solutions.

Located at Lunastigen 5, Box 1086, Huddinge, 14122, SE, Medivir AB values collaboration and partnerships as integral components of its business model. The company's shares, traded under the ticker MVIR, are listed on Nasdaq Stockholm's Small Cap list. We invite the management team at Medivir AB to enhance your company’s presence with a customized and exclusive company showcase and product listing on our platform.